학술논문
Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
Document Type
Article
Source
Subject
*FIBROBLAST growth factor receptors
*PATIENT selection
*NUCLEIC acid hybridization
*GENE expression
*GENE fusion
*
*
*
*
Language
ISSN
2073-4409
Abstract
Inhibitors of fibroblast growth factor receptor (FGFR) signaling have been investigated in various human cancer diseases. Recently, the first compounds received FDA approval in biomarker-selected patient populations. Different approaches and technologies have been applied in clinical trials, ranging from protein (immunohistochemistry) to mRNA expression (e.g., RNA in situ hybridization) and to detection of various DNA alterations (e.g., copy number variations, mutations, gene fusions). We review, here, the advantages and limitations of the different technologies and discuss the importance of tissue and disease context in identifying the best predictive biomarker for FGFR targeting therapies. [ABSTRACT FROM AUTHOR]